(88 days)
MARS Holter Analysis Workstation is designed for acquisition, analysis, edit, review, report and storage of ambulatory ECG data. Results of the automated analysis are intended to assist the physician in the interpretation of the recorded data. This information is not intended to serve as a substitute for the physician overread of the recorded ECG data. The MARS Holter Analysis Workstation is intended to be used by trained operators under the direct supervision of a licensed healthcare practitioner in a hospital or clinic environment. Patient population includes both adult and pediatric (greater than 10Kg) human patients. The MARS Holter Analysis Workstation provides the user arrhythmia studies and holter analysis capabilities.
Data acquired may be use for the following indications:
- Evaluation of symptoms that may be caused by cardiac arrhythmia and/or conduction disturbances
- Evaluation of symptoms that may be due to myocardial ischemia
- Detection of ECG events that alter prognosis in certain forms of heart disease
- Detection and analysis of pacemaker function and failure
- Determination of cardiac response to lifestyle
- Evaluation of therapeutic interventions
- Investigations in epidemiology and clinical trials
The MARS Holter Analysis Workstation system is a software-system that runs on PC based hardware. The MARS Holter Analysis Workstation supports a number of software applications including analysis, user editing and final report processing.
The MARS Holter Analysis Workstation analyzes ambulatory ECG data, to detect and label beats, and then presents it in a variety of screens to the user for review and data editing purposes. The MARS Holter Analysis Workstation system stores and prints final reports and allows reports to be sent to the MUSE Cardiology Information Management System for long- term archive. The MARS Holter Analysis Workstation supports acquisition from ambulatory ECG Recorders. A variety of different final report formats can be stored and printed. The final report is used by trained medical personal to diagnosis a patient's cardiac abnormalities.
Here's an analysis of the provided text regarding the MARS Holter Analysis Workstation's acceptance criteria and study information:
1. Table of Acceptance Criteria and Reported Device Performance:
The provided text does not explicitly state specific numerical acceptance criteria for the MARS Holter Analysis Workstation. Instead, it relies on a statement of substantial equivalence to predicate devices and adherence to voluntary standards and quality assurance measures.
Therefore, the table will reflect this qualitative approach.
| Acceptance Criterion | Reported Device Performance |
|---|---|
| Overall Safety and Effectiveness: Device should be as safe and effective as predicate devices. | "The results of these measurements demonstrated that the MARS Holter Analysis Workstation is as safe, as effective, and performs as well as the predicate devices." (Predicate devices: K991786 GEMS-IT MARS Unity Workstation, K010949 Agilent Technologies 2010 Plus Holter for Windows). |
| Compliance with Voluntary Standards: Device should comply with relevant voluntary standards. | "The MARS complies with the voluntary standards as detailed in Section 9 of this submission." (Specific standards not detailed in this extract). |
| Quality Assurance Measures: Development should adhere to established quality assurance processes. | "The following quality assurance measures were applied to the development of the device:Requirements specification reviewRisk analysisSoftware and hardware testingPerformance testingSafety testingEnvironmental testingClinical use evaluationFinal validation" |
| Functional Equivalence: Device should employ the same technology and functionality as predicate devices. | "The proposed MARS Holter Analysis Workstation employs the same functional scientific technology as the predicate devices MARS Unity (K991786) and 2010 Plus Holter for Windows (K010949)." |
2. Sample Size Used for the Test Set and Data Provenance:
The provided text does not specify a sample size or data provenance (e.g., country of origin, retrospective/prospective) for a distinct "test set." The document mentions "clinical use evaluation" as a quality assurance measure, but no details of such a study are provided. The "results of these measurements" (referring to the quality assurance measures) form the basis for the conclusion that the device performs as well as predicate devices.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications:
The provided text does not specify the number or qualifications of experts used to establish ground truth for any test set. While the intended use states that "Results of the automated analysis are intended to assist the physician in the interpretation of the recorded data" and "This information is not intended to serve as a substitute for the physician overread of the recorded ECG data," it doesn't detail how this physician overread was used in a testing context.
4. Adjudication Method for the Test Set:
The provided text does not describe any adjudication method (e.g., 2+1, 3+1, none) for a test set.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, and its effect size:
The provided text does not indicate that a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was performed, nor does it mention any effect size related to human reader improvement with or without AI assistance. The focus is on the device's standalone performance compared to predicate devices, with the understanding that a trained operator and physician will be supervising and interpreting the results.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done:
Yes, a standalone performance assessment was effectively done. The document states that the MARS Holter Analysis Workstation "analyzes ambulatory ECG data, to detect and label beats, and then presents it in a variety of screens to the user." The "results of these measurements demonstrated that the MARS Holter Analysis Workstation is as safe, as effective, and performs as well as the predicate devices." This implies that the algorithm's performance in analyzing ECG data was evaluated independently as part of the "performance testing" and "final validation" phases mentioned in the quality assurance measures. The focus is on the system's ability to perform the analysis, even though the output is for physician review.
7. The Type of Ground Truth Used:
The provided text does not explicitly state the type of ground truth used (e.g., expert consensus, pathology, outcomes data). Given the nature of Holter analysis and the reliance on predicate devices, it's highly probable that ground truth would involve:
- Established interpretations by qualified cardiologists/electrophysiologists from previously analyzed Holter recordings.
- Comparison against outputs of the predicate devices which themselves would have been validated against expert interpretation or established clinical standards.
8. The Sample Size for the Training Set:
The provided text does not specify the sample size for the training set.
9. How the Ground Truth for the Training Set was Established:
The provided text does not explicitly state how the ground truth for the training set was established.
{0}------------------------------------------------
JUL 1 9 2005
KDS1026 8/ / 2
Section 2 Summary and Certification
| 510(k) Summary of Safety and Effectiveness | |
|---|---|
| Date: | April 20, 2005 |
| Submitter: | GE Medical Systems Information Technologies8200 West Tower AvenueMilwaukee, WI 53223 USA |
| Contact Person: | Lisa M. BaumhardtRegulatory Affairs SpecialistGE Medical Systems Information TechnologiesPhone: (262) 293-1699Fax: (262) 293-1460 |
| Device: Trade Name: | MARS Holter Analysis Workstation |
| Common/Usual Name: | Holter Analysis Workstation |
| Classification Names: | 21 CFR 870.1425 Programmable Diagnostic Computer |
| Predicate Devices: | K991786 GEMS-IT MARS Unity WorkstationK010949 Agilent Technologies 2010 Plus Holter for Windows |
| Device Description: | The MARS Holter Analysis Workstation system is a software-systemthat runs on PC based hardware. The MARS Holter AnalysisWorkstation supports a number of software applications includinganalysis, user editing and final report processing.The MARS Holter Analysis Workstation analyzes ambulatory ECGdata, to detect and label beats, and then presents it in a variety ofscreens to the user for review and data editing purposes. The MARSHolter Analysis Workstation system stores and prints final reports andallows reports to be sent to the MUSE Cardiology InformationManagement System for long- term archive. The MARS HolterAnalysis Workstation supports acquisition from ambulatory ECGRecorders. A variety of different final report formats can be stored andprinted. The final report is used by trained medical personal todiagnosis a patient's cardiac abnormalities. |
| Intended Use: | MARS Holter Analysis Workstation is designed for acquisition, analysis,edit, review, report and storage of ambulatory ECG data. Results of theautomated analysis are intended to assist the physician in theinterpretation of the recorded data. This information is not intended toserve as a substitute for the physician overread of the recorded ECGdata. The MARS Holter Analysis Workstation is intended to be used bytrained operators under the direct supervision of a licensed healthcarepractitioner in a hospital or clinic environment. Patient populationincludes both adult and pediatric (greater than 10Kg) human patients.The MARS Holter Analysis Workstation provides the user arrhythmiastudies and holter analysis capabilities. |
{1}------------------------------------------------
p. 2/2
Data acquired may be use for the following indications:
- . Evaluation of symptoms that may be caused by cardiac arrhythmia and/or conduction disturbances
- Evaluation of symptoms that may be due to myocardial . ischemia
- . Detection of ECG events that alter prognosis in certain forms of heart disease
- Detection and analysis of pacemaker function and failure .
- Determination of cardiac response to lifestyle .
- . Evaluation of therapeutic interventions
- Investigations in epidemiology and clinical trials .
- The proposed MARS Holter Analysis Workstation employs the same Technology: functional scientific technology as the predicate devices MARS Unity (K991786) and 2010 Plus Holter for Windows (K010949)
- The MARS complies with the voluntary standards as defailed in Section Test Summary: 9 of this submission. The following quality assurance measures were applied to the development of the device:
- Requirements specification review .
- Risk analysis .
- Software and hardware testing .
- Performance testing .
- Safety testing .
- Environmental testing ◆
- . Clinical use evaluation
- Final validation .
Conclusion:
The results of these measurements demonstrated that the MARS Holter Analysis Workstation is as safe, as effective, and performs as well as the predicate devices.
{2}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three lines forming its body and head. The eagle is encircled by the text "DEPARTMENT OF HEALTH AND HUMAN SERVICES. USA" in a circular arrangement. The text is in all caps and appears to be in a sans-serif font.
JUL 1 9 2005
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
General Electric Medical Systems Information Technologies c/o Lisa Baumhardt Regulatory Affairs Specialist 8200 West Tower Avenue Milwaukee, WI 53223
Re: K051026
K051020
Trade Name: MARS Holter Analysis Workstation
Trade Name: MARS Holter 270-1405 Trade : Number: 21 CFR 870.1425 Regulation Number. 21 Crici - Programmable Diagnostic Computer Regulatory Class: Class II (two) Product Code: DQK Dated: April 20, 2005 Received: April 22, 2005
Dear Ms. Baumhardt:
We have reviewed your Section 510(k) premarket notification of intent to market the device is We have reviewed your Section 5 I ((L) premarket in mailvent (for the indications
referenced above and have device is substantialy equivalent (for the indications referenced above and have determined the devices marketed in interstate
for use stated in the enclosure) to legally marketed previces marketed in interstate for use stated in the enclosure) to legally marketed previce manice America Amendments, or to
commerce prior to May 28, 1976, the enactment date of the Federal Food, Drug, commerce prior to May 28, 1976, the enactment with the provisions of the Federal Food, Drug,
devices that have been reclassified in accordance with the provisions of the Fede devices that have been reclassified in accordance with the proval application (PMA).
and Cosmetic Act (Act) that and require approval of a preval application (PMA). and Cosmetic Act (Act) that do not require approval or approvations of the Act. The
You may, therefore, market the device, subject to the general ontrols provisions of the You may, therefore, market the device, subject to the general connual registration, listing of
general controls provisions of the Act include requirements for annual registra general controls provisions of the Act include requirements to them and one of the management in adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it
ed its can be and the call of the case of a Fricting major regulatio If your device is classified (see above) into either class in (special Conadions affecting your device can
may be subject to such additional controls: Existing major regulat may be subject to such additional controls. Exismig major regantals be found in the Code of Federal Regulations, Print 27, 2011
publish further announcements concerning your device in the Federal Register.
{3}------------------------------------------------
Page 2 – Ms. Lisa Baumhardt
Please be advised that FDA's issuance of a substantial equivalence determination does not mean Please or advised that I DA 3 tosaanse vice complies with other requirements of the Act that I DA has made a actor regulations administered by other Federal agencies. You must of ally I coleral statutes and regaranents, including, but not limited to: registration and listing (21 Comply with an the Act 8 requirements, 01); good manufacturing practice requirements as set CTN in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic forth in the quality systems (Sections 531-542 of the Act); 21 CFR 1000-1050. product radiation control provins (seting your device as described in your Section 510(k) I his icter will anow you've oogin maing of substantial equivalence of your device to a legally premarket notification: "The PDF miamig of castion for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please If you desire specific advice for your act (301) 594-4646. Also, please note the regulation entitled, Connact the Office of Comp to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small other general international and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
B. Zimmerman for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Indications for Use
510(k) Number (if known): __ Ko 51026 Device Name: MARS® Holter Analysis Workstation
Indications for Use:
$
MARS Hotter Analysis Workstation is designed for acquisition, analysis, edit, review, report and storage of ambulatory ECG data. Results of the automated analysis are intended to assist the physician in the interpretation of the recorded data. This information is not intended to serve as a substitute for the physician overread of the recorded ECG data. The MARS Holter Analysis Workstation is intended to be used by trained operators under the direct supervision of a licensed healthcare practitioner in a hospital or clinic environment. Patient population includes both adult nodiatric (greater than 10Kg) human patients. The MARS Holter Analysis Workstation provides the user arrhythmia studies and holter analysis capabilities.
Data acquired may be use for the following indications:
- Evaluation of symptoms that may be caused by cardiac arrhythmia and/or conduction . disturbances
- Evaluation of symptoms that may be due to myocardial ischemia .
- Detection of ECG events that alter prognosis in certain forms of heart disease .
- Detection and analysis of pacemaker function and failure ●
- Determination of cardiac response to lifestyle .
- Evaluation of therapeutic interventions ●
- Investigations in epidemiology and clinical trials ●
Prescription Use × (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER
PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Alummo
Sivision Sign-Off) Division of Cardlovascular Devices 251026 510(k) Number_
Page I of
§ 870.1425 Programmable diagnostic computer.
(a)
Identification. A programmable diagnostic computer is a device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes, transducers, or measuring devices; this device includes any associated commercially supplied programs.(b)
Classification. Class II (performance standards).